Phase IIIb Comparison of BARACLUDE
Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy versus BARACLUDE plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
San Francisco, CA (PRWEB) November 09, 2011
Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BE‐LOW™ study, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (0.5mg once daily) with BARACLUDE (0.5mg once daily) plus tenofovir (300mg once daily) in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) with compensated liver disease. In this study, no statistically significant difference was observed between the two treatment arms in the primary efficacy endpoint of HBV DNA
“In these 96-week data comparing entecavir monotherapy to combination of entecavir plus tenofovir, we found that combination therapy did not result in statistically significant difference in virologic response compared to entecavir monotherapy. The BE-LOW study data confirmed the results of previous studies showing limited or no benefit of combination therapy compared to monotherapy for treatment-naïve patients with chronic hepatitis B,” said principal investigator Anna Lok, MD, FRCP, director of clinical hepatology and professor in the department of internal medicine at the University of Michigan Medical School in Ann Arbor.
Study Results
In this study, 379 nucleos(t)ide-naïve patients with CHB were randomized to receive either BARACLUDE (entecavir) 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Key findings at week 96 are:
A comparable proportion of patients in both treatment arms achieved the primary efficacy endpoint of HBV DNA
Among HBeAg-positive patients, the proportion achieving HBV DNA
Among HBeAg-negative patients, the proportion achieving HBV DNA
Secondary efficacy endpoints measured in the study included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and HBeAg loss. ALT normalization was observed in 81.9% (149/182) of patients in this study in the BARACLUDE (entecavir) monotherapy arm versus 69% (136/197) in the BARACLUDE plus tenofovir arm. HBeAg seroconversion was observed in 32.5% (41/126) of patients in the BARACLUDE (entecavir) monotherapy arm versus 21.7% (30/138) in the BARACLUDE plus tenofovir arm in this study.
Two patients (1.1%) in the BARACLUDE monotherapy arm compared to five patients (2.5%) in the BARACLUDE plus tenofovir arm discontinued treatment prior to week 96. Patients who discontinued therapy prior to week 96 were considered treatment failures.
The overall adverse event profiles were similar across study arms. A total of three deaths occurred among treated patients, all on the BARACLUDE plus tenofovir arm: one due to bile duct tumor; one due to a late-onset exacerbation of hepatitis which was associated with breakthrough viremia while on continued treatment; and one due to cardiac arrest. One patient (0.5%) in the BARACLUDE monotherapy arm and two patients (1.0%) in the BARACLUDE plus tenofovir arm experienced on treatment ALT flares, defined as greater than 2 x baseline ALT and greater than 10 x ULN. No patients (0.0%) in either arm experienced off-treatment ALT flares. Six patients (3.3%) in the BARACLUDE monotherapy arm and four (2.0%) patients in the BARACLUDE plus tenofovir arm experienced serum creatinine increase ≥0.3 mg/dL. A total of five malignancies occurred among patients in the study: four (2.2%) patients in the BARACLUDE monotherapy arm and one (0.5%) patient in the BARACLUDE plus tenofovir arm. In the BARACLUDE monotherapy arm, there were three diagnoses of hepatocellular carcinoma (two on-treatment and one off-treatment) and one case of gastric cancer. In the BARACLUDE plus tenofovir arm there was one case of breast cancer.
Two patients (1.0%) in the BARACLUDE monotherapy arm and seven patients (3.6%) in the BARACLUDE plus tenofovir arm experienced virologic breakthrough. No recognized genotypic resistance mutations were observed in either treatment arm.
About The Study
The BE-LOW study is an open-label, multicenter, Phase IIIb study of 379 nucleos(t)ide-naïve patients with CHB. The patients were randomized 1:1 and treated with either BARACLUDE 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Nucleos(t)ide-naïve, HBeAg-negative CHB patient enrollment was capped at 30%. The primary efficacy endpoint was the proportion of patients with HBV DNA
About Chronic Hepatitis B
Approximately 350 million people worldwide are chronically infected with hepatitis B (approximately 5% of the world’s population) and 75% of these cases occur in the Asia-Pacific region.(2) Most people with chronic hepatitis B show no signs or symptoms, so many of those chronically infected are unaware of their status. A blood test can diagnose chronic hepatitis B. Patients should speak with their doctor about options available for this condition.
About BARACLUDE®
Discovered at Bristol-Myers Squibb, BARACLUDE® is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:
compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis
decompensated liver disease
For full prescribing information for BARACLUDE®, please consult the Summary of Product Characteristics.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb Company.
Contacts:
Bristol-Myers Squibb
Media: Annie Simond, +33 1 58 83 65 66, annie.simond(at)bms(dot)com
Note:
(1) HBV DNA carries the genetic blueprint of the hepatitis B virus. The number of HBV DNA “copies” found in a person’s blood, or “viral load,” indicates how rapidly the virus is reproducing in their liver. Low levels of HBV DNA, recognized as 300 copies per milliliter or less, indicate an “inactive” hepatitis B infection.
Reference:
(2) Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2:50 – 57. Available from http://www.medsci.org/v02p0050.htm Accessed November 2011
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Related Breast Cancer Prevention Press Releases
Winning Edge Designs Breast Cancer Prevention Rose Head CoverBreast Cancer Prevention Rose 460cc Golf Headcover Nice…
Day-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EA – Show your support for breast cancer research with a Pink Ribbon Desk Calendar Refill. Day-Timer contributes 10 percent of the proceeds to The Breast Cancer Research Foundation to achieve the prevention and cure of breast cancer. Pink Ribbon design on white 3-1/2″ x 6″ pages coordinates with other Pink Ribbon products. Each two-page-per-day offers hourly appointment times from 7 AM to 5 PM and past, currenDay-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EAShow your support for breast cancer re…
Breast Cancer: Risks and Prevention, Diagnosis & TreatmentsWhat are the risk factors for breast cancer and what decisions will a woman need to make on the basis of an abnormal mammogram res…
Categories: Breast Cancer Prevention Tags: , Arms, BARACLUDE, between, Combination, Comparison, Difference, entecavir, IIIb, Monotherapy, Phase, plus, Shows, Statistical, Study, Tenofovir, versus
Treatment of rectal cancer varies enormously between different European countries
First results from an international comparison of the care of patients with rectal cancer have shown there are substantial differences in the use of chemotherapy and radiotherapy between European countries. The European Registration of Cancer Care study compared the treatment of 6,597 patients in Sweden, Norway, Denmark and the Netherlands who were diagnosed with rectal cancer between 2008 and 2009.
ScienceDaily: Cancer News
Husbands and Heroes The Breast Cancer Caregiver: A Guide to Help and Thank You for all You DoBrenda Coffee pulls no punches when talking to breast cancer husbands. No subject is off limits, and she keeps her message short a…
Treat Her Like a Princess: How to Help Your Girlfriend with Breast CancerAn uplifting celebration of life written by a cancer survivor, this sassy and inspirational handbook provides information and guid…
When Your Wife Has Breast Cancer…: A Story of Love, Courage and SurvivalMark Weiss tells the story of his 38-year-old wife Cathy’s battle with breast cancer. It examines the choices they had, the decisi…
Categories: Breast Cancer Caregiver Tags: between, Cancer, Countries, Different, enormously, European, rectal, Treatment, Varies
Possible link between two Type 2 diabetes drugs and pancreatic cancer, suggested by new research
Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer.
ScienceDaily: Cancer News
Treat Her Like a Princess: How to Help Your Girlfriend with Breast CancerAn uplifting celebration of life written by a cancer survivor, this sassy and inspirational handbook provides information and guid…
The Breast Cancer Caregiver’s Survival Guide: Practical Tips for Supporting Your Wife through Breast CancerOne of the worst possible things has happened to you. You’ve gotten the bad news from your wife’s doctor, and the two of you a…
For The Women We Love: A Breast Cancer Action Plan and Caregiver’s Guide for MenWhen a woman is diagnosed with breast cancer, it is vital that the men in their life move beyond traditional roles, adding new res…
Categories: Breast Cancer Caregiver Tags: between, Cancer, Diabetes, drugs, link, Pancreatic, Possible, research, suggested, type
Critical Similarity Revealed Between Two Types Of Do-It-All Stem Cells
Ever since human induced pluripotent stem cells were first derived in 2007, scientists have wondered whether they were functionally equivalent to embryonic stem cells, which are sourced in early-stage embryos. Both cell types have the ability to differentiate into any cell in the body, but their origins – in embryonic and adult tissue – suggest that they are not identical. Although both cell types have great potential in basic biological research and in cell- and tissue-replacement therapy, the newer form, called IPS cells, have two advantages…
Health News from Medical News Today
Biomarkers in Breast Cancer (Cancer Drug Discovery and Development)Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and ex…
This digital document is an article from OB GYN News, published by International Medical News Group on February 15, 2008. The leng…
Categories: Breast Cancer Drugs Tags: between, cells, Critical, DoItAll, Revealed, Similarity, stem, Types
No Link Found Between Menopause And Increased Risk Of Fatal Heart Attack
Johns Hopkins researchers say data show aging alone, not hormonal impact of menopause, explains increasing number of deaths as women age Contradicting the long-held medical belief that the risk of cardiovascular death for women spikes sharply after menopause, new research from Johns Hopkins suggests instead that heart disease mortality rates in women progress at a constant rate as they age…
Health News from Medical News Today
Tamoxifen and Breast Cancer (Yale Fastback Series)A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tam…
Medical Marijuana Pot Hemp Legalize Cannabis Weed Tie Bar ClipThis is a great conversation piece showing your support for the controversial issue of medical Marijuana. This item is unique and …
Medical Marijuana Pot Hemp Legalize Cannabis Weed Lapel Pin Tie TackThis is a great conversation piece showing your support for the controversial issue of medical Marijuana. This item is unique and …
Categories: Breast Cancer Drugs Tags: attack, between, Fatal, found, Heart, Increased, link, menopause, Risk
Study finds association between blood biomarker and risk of death
In an analysis of data from two separate study groups, elderly men and women who had higher levels of the protein biomarker cathepsin S in their blood had an increased risk of death, according to a new study. This biomarker might have a relationship with the development of cardiovascular disease and cancer.
ScienceDaily: Cancer News
Surviving Your Wife’s Cancer: A Guide For Husbands Whose Wives Have Been Diagnosed With CancerStan Scott lost his wife to sarcoma in 1991. Realizing that many men were going through the same emotional and physical trauma he …
Healing Yourself! 23 Ways to Heal Diseases & Health IssuesBrent Atwater’s Just Plain Love(R) Books presentsHealing Yourself! 23 Ways to Heal Diseases, Disorders, Medical Conditions & Healt…
The Pebble Path: Returning Home from a Forest of ShadowsBreast cancer! Few words strike more fear into one’s heart than these. Yet the author faced that very diagnosis, twice! How did sh…
Categories: Breast Cancer Caregiver Tags: Association, between, Biomarker, Blood, Death, finds, Risk, Study
Link Between Long Term Mobile Phone Use And Brain Tumours
Two papers have been published online in Occupational and Environmental Medicine. They show for the first time that there is a dose response effect for the risk of brain tumours among the heaviest users of mobile phones. Before this study, there was only an indication of an increased risk, but with no correlation with length of exposure, which could have been due to bias…
Cancer / Oncology News From Medical News Today
Alpen National Breast Cancer Foundation 8 x 25 Wide Angle Porro Prism Compact BinocularAlpen Optics is the first optics company to partner with the National Breast Cancer Foundation with our new Pink Series Binocular …
Day-Timer Products – Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 Each – Get organized and support breast cancer research at the same time. – Day-Timer will donate approximately 3%-10% of the retail price of this item to the Breast Cancer Research Foundation. – Includes 12 months of undated weekly and monthly pages. – Address/phone directory keeps contacts at your fingertips. -Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 EachGet organized and support …
Keep-A-Breast 1 Inch I Love Boobies Bracelet Black/WhiteThe Keep A Breast Foundation I Love Boobies Silicone Bracelet. 50% of the sale of this bracelet benefits Keep A Breast’s preventio…
Breast Cancers Arising between Mammograms Have Aggressive Features
Breast cancers that are discovered in the period between regular screening mammograms—known as interval cancers—are more likely to have features associated with aggressive behavior and a poor prognosis than cancers found via screening mammograms. These high-risk features include higher stage and grade, larger size, and lack of estrogen receptors (ER) and progesterone receptors (PR), researchers reported online May 3 in the Journal of the National Cancer Institute.
NCI Cancer Bulletin
Life’s Delicate Balance: Causes and Prevention of Breast CancerWith breast cancer rates soaring, Life’s Delicate Balance defines and documents many causes highlighting means to prevention.Appli…
Prepackaged (7 3/4 in.) BREAST Cancer Awareness Bracelet, 8mmProduct Description
Our Bracelets are Handmade in the USA. Made with 8mm cats eye beads, silver plated 5mm round beads,silver plat…
Pink Silicone Bracelets (50 per bag)Each pink silicone bracelet says hope, faith, love with ribbons. A great gift to say thank you to anyone who gave you money for yo…
Breast Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages. Everything You Need to Know About Breast CancerThis book is for people who have breast cancer, as well as for their family members, friends, students, and others who want to fin…
Categories: Breast Cancer Causes Tags: Aggressive, Arising, between, Breast, Cancers, Features, mammograms
Breast cancers found between mammograms more likely to be aggressive
Breast cancers that are first detectable in the interval between screening mammograms are more likely to be aggressive, fast-growing tumors according to a new study.
ScienceDaily: Cancer News
The Breast Cancer Caregivers Survival Guide: Practical Tips for Supporting Your Wife through Breast CancerOne of the worst possible things has happened to you. You’ve gotten the bad news from your wife’s doctor, and the two of you …
When Your Wife Has Breast Cancer…: A Story of Love, Courage and SurvivalMark Weiss tells the story of his 38-year-old wife Cathy’s battle with breast cancer. It examines the choices they had, the decisi…
21st Century Understanding Cancer Toolkit: Coping with Advanced Cancer – Metastatic Cancer, Caregiver Support, Palliative Care and Hospice, Advance Directives, End-of-Life Care, Pain Control, GriefThis massive guide, with over 600 pages and 23 chapters, has authoritative information and practical advice from the nation’s canc…
Categories: Breast Cancer Caregiver Tags: Aggressive, between, Breast, Cancers, found, likely, mammograms, More
Association found between industry funding and promotional pieces on menopausal hormone therapy
There may be a link between receiving industry funding for speaking, consulting, or research, and the publication of apparently promotional opinion pieces on menopausal hormone therapy. Furthermore, such publications may encourage physicians to continue prescribing these therapies to women of menopausal age.
ScienceDaily: Cancer News
Treat Her Like a Princess: How to Help Your Girlfriend with Breast CancerAn uplifting celebration of life written by a cancer survivor, this sassy and inspirational handbook provides information and guid…
21st Century Understanding Cancer Toolkit: Coping with Advanced Cancer – Metastatic Cancer, Caregiver Support, Palliative Care and Hospice, Advance Directives, End-of-Life Care, Pain Control, GriefThis massive guide, with over 600 pages and 23 chapters, has authoritative information and practical advice from the nation’s canc…
When Your Wife Has Breast Cancer…: A Story of Love, Courage and SurvivalMark Weiss tells the story of his 38-year-old wife Cathy’s battle with breast cancer. This is an open and honest account of a fami…
Categories: Breast Cancer Caregiver Tags: Association, between, found, Funding, Hormone, industry, menopausal, pieces, promotional, therapy
